Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries

Pamela Ouyang, Jean Claude Tardif, David M. Herrington, Kerry J. Stewart, Paul D. Thompson, Mary N. Walsh, Susan K. Bennett, Alan W. Heldman, Matthew A. Tayback, Nae Yuh Wang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Clinical trials indicate that hormone therapy (HT) does not decrease cardiovascular disease events or angiographic coronary disease progression. The effects of HT on SVG vessels are unknown. To determine whether postmenopausal hormone therapy started after coronary bypass surgery (CABG) decreases saphenous vein graft (SVG) disease, we conducted a multicenter randomized placebo-controlled angiographic study of estradiol ± medroxyprogesterone started within 6 months of CABG in 83 postmenopausal women. Angiographic and intravascular ultrasound (IVUS) assessment at 6 and 42 months was planned to assess SVG disease progression. The study was stopped early following publication of the Women's Health Initiative Estrogen/Progestin study. Eighty-three subjects underwent a 6-month angiogram with 63 undergoing IVUS. Forty-five subjects completed the 42-month angiogram (20 underwent 42-month IVUS). In analysis of paired 6- and 42-month angiogram and IVUS studies, HT slowed angiographic progression of SVG disease assessed by mean percent stenosis (p < 0.001), minimal lumen diameter (p = 0.029), and total plaque volume (p = 0.006). In contrast, HT accelerated disease progression in non-bypassed native coronary arteries (minimum lumen diameter, p = 0.01). SVG disease and closure occurred in 38% subjects within 1-year post-CABG. The groups had similar frequency of cardiovascular events expect for angioplasty that occurred in eight HT compared to one placebo subject (p < 0.05). In HT subjects angioplasty was indicated for native coronary arterial stenoses while in the placebo subject angioplasty was indicated for SVG stenosis. This study suggests that hormone treatment may slow SVG disease progression while accelerating atherosclerosis in non-bypassed native coronary arteries.

Original languageEnglish
Pages (from-to)375-386
Number of pages12
JournalAtherosclerosis
Volume189
Issue number2
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Saphenous Vein
Disease Progression
Coronary Vessels
Hormones
Transplants
Angioplasty
Angiography
Placebos
Therapeutics
Pathologic Constriction
Medroxyprogesterone
Coronary Stenosis
Women's Health
Progestins
Coronary Disease
Publications
Estradiol
Atherosclerosis
Estrogens
Cardiovascular Diseases

Keywords

  • Angiographic trial
  • Coronary artery bypass surgery
  • Postmenopausal hormone therapy
  • Saphenous vein graft

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. / Ouyang, Pamela; Tardif, Jean Claude; Herrington, David M.; Stewart, Kerry J.; Thompson, Paul D.; Walsh, Mary N.; Bennett, Susan K.; Heldman, Alan W.; Tayback, Matthew A.; Wang, Nae Yuh.

In: Atherosclerosis, Vol. 189, No. 2, 01.12.2006, p. 375-386.

Research output: Contribution to journalArticle

Ouyang, Pamela ; Tardif, Jean Claude ; Herrington, David M. ; Stewart, Kerry J. ; Thompson, Paul D. ; Walsh, Mary N. ; Bennett, Susan K. ; Heldman, Alan W. ; Tayback, Matthew A. ; Wang, Nae Yuh. / Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. In: Atherosclerosis. 2006 ; Vol. 189, No. 2. pp. 375-386.
@article{0f1914c4f65a4fb09c57a70018051f74,
title = "Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries",
abstract = "Clinical trials indicate that hormone therapy (HT) does not decrease cardiovascular disease events or angiographic coronary disease progression. The effects of HT on SVG vessels are unknown. To determine whether postmenopausal hormone therapy started after coronary bypass surgery (CABG) decreases saphenous vein graft (SVG) disease, we conducted a multicenter randomized placebo-controlled angiographic study of estradiol ± medroxyprogesterone started within 6 months of CABG in 83 postmenopausal women. Angiographic and intravascular ultrasound (IVUS) assessment at 6 and 42 months was planned to assess SVG disease progression. The study was stopped early following publication of the Women's Health Initiative Estrogen/Progestin study. Eighty-three subjects underwent a 6-month angiogram with 63 undergoing IVUS. Forty-five subjects completed the 42-month angiogram (20 underwent 42-month IVUS). In analysis of paired 6- and 42-month angiogram and IVUS studies, HT slowed angiographic progression of SVG disease assessed by mean percent stenosis (p < 0.001), minimal lumen diameter (p = 0.029), and total plaque volume (p = 0.006). In contrast, HT accelerated disease progression in non-bypassed native coronary arteries (minimum lumen diameter, p = 0.01). SVG disease and closure occurred in 38{\%} subjects within 1-year post-CABG. The groups had similar frequency of cardiovascular events expect for angioplasty that occurred in eight HT compared to one placebo subject (p < 0.05). In HT subjects angioplasty was indicated for native coronary arterial stenoses while in the placebo subject angioplasty was indicated for SVG stenosis. This study suggests that hormone treatment may slow SVG disease progression while accelerating atherosclerosis in non-bypassed native coronary arteries.",
keywords = "Angiographic trial, Coronary artery bypass surgery, Postmenopausal hormone therapy, Saphenous vein graft",
author = "Pamela Ouyang and Tardif, {Jean Claude} and Herrington, {David M.} and Stewart, {Kerry J.} and Thompson, {Paul D.} and Walsh, {Mary N.} and Bennett, {Susan K.} and Heldman, {Alan W.} and Tayback, {Matthew A.} and Wang, {Nae Yuh}",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.atherosclerosis.2005.12.015",
language = "English",
volume = "189",
pages = "375--386",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries

AU - Ouyang, Pamela

AU - Tardif, Jean Claude

AU - Herrington, David M.

AU - Stewart, Kerry J.

AU - Thompson, Paul D.

AU - Walsh, Mary N.

AU - Bennett, Susan K.

AU - Heldman, Alan W.

AU - Tayback, Matthew A.

AU - Wang, Nae Yuh

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Clinical trials indicate that hormone therapy (HT) does not decrease cardiovascular disease events or angiographic coronary disease progression. The effects of HT on SVG vessels are unknown. To determine whether postmenopausal hormone therapy started after coronary bypass surgery (CABG) decreases saphenous vein graft (SVG) disease, we conducted a multicenter randomized placebo-controlled angiographic study of estradiol ± medroxyprogesterone started within 6 months of CABG in 83 postmenopausal women. Angiographic and intravascular ultrasound (IVUS) assessment at 6 and 42 months was planned to assess SVG disease progression. The study was stopped early following publication of the Women's Health Initiative Estrogen/Progestin study. Eighty-three subjects underwent a 6-month angiogram with 63 undergoing IVUS. Forty-five subjects completed the 42-month angiogram (20 underwent 42-month IVUS). In analysis of paired 6- and 42-month angiogram and IVUS studies, HT slowed angiographic progression of SVG disease assessed by mean percent stenosis (p < 0.001), minimal lumen diameter (p = 0.029), and total plaque volume (p = 0.006). In contrast, HT accelerated disease progression in non-bypassed native coronary arteries (minimum lumen diameter, p = 0.01). SVG disease and closure occurred in 38% subjects within 1-year post-CABG. The groups had similar frequency of cardiovascular events expect for angioplasty that occurred in eight HT compared to one placebo subject (p < 0.05). In HT subjects angioplasty was indicated for native coronary arterial stenoses while in the placebo subject angioplasty was indicated for SVG stenosis. This study suggests that hormone treatment may slow SVG disease progression while accelerating atherosclerosis in non-bypassed native coronary arteries.

AB - Clinical trials indicate that hormone therapy (HT) does not decrease cardiovascular disease events or angiographic coronary disease progression. The effects of HT on SVG vessels are unknown. To determine whether postmenopausal hormone therapy started after coronary bypass surgery (CABG) decreases saphenous vein graft (SVG) disease, we conducted a multicenter randomized placebo-controlled angiographic study of estradiol ± medroxyprogesterone started within 6 months of CABG in 83 postmenopausal women. Angiographic and intravascular ultrasound (IVUS) assessment at 6 and 42 months was planned to assess SVG disease progression. The study was stopped early following publication of the Women's Health Initiative Estrogen/Progestin study. Eighty-three subjects underwent a 6-month angiogram with 63 undergoing IVUS. Forty-five subjects completed the 42-month angiogram (20 underwent 42-month IVUS). In analysis of paired 6- and 42-month angiogram and IVUS studies, HT slowed angiographic progression of SVG disease assessed by mean percent stenosis (p < 0.001), minimal lumen diameter (p = 0.029), and total plaque volume (p = 0.006). In contrast, HT accelerated disease progression in non-bypassed native coronary arteries (minimum lumen diameter, p = 0.01). SVG disease and closure occurred in 38% subjects within 1-year post-CABG. The groups had similar frequency of cardiovascular events expect for angioplasty that occurred in eight HT compared to one placebo subject (p < 0.05). In HT subjects angioplasty was indicated for native coronary arterial stenoses while in the placebo subject angioplasty was indicated for SVG stenosis. This study suggests that hormone treatment may slow SVG disease progression while accelerating atherosclerosis in non-bypassed native coronary arteries.

KW - Angiographic trial

KW - Coronary artery bypass surgery

KW - Postmenopausal hormone therapy

KW - Saphenous vein graft

UR - http://www.scopus.com/inward/record.url?scp=33750385172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750385172&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2005.12.015

DO - 10.1016/j.atherosclerosis.2005.12.015

M3 - Article

C2 - 16442114

AN - SCOPUS:33750385172

VL - 189

SP - 375

EP - 386

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -